SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2016 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, today announced its participation in two upcoming investor conferences:
- Canaccord Genuity Rare Disease, BioPharma 1x1 Day
Tuesday, February 2, 2016
Omni Berkshire Place Hotel, New York, NY
- SunTrust Robinson Humphrey 2016 Orphan Drug Day
Tuesday, February 23, 2016
JW Marriott Essex House, New York, NY
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with unmet medical needs in diseases that have seen limited therapeutic innovation, with an initial focus on immunotherapy and oncology. Atara Bio’s programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL and WT1-CTL and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.
INVESTOR & MEDIA CONTACT: Investors: Steve Klass 212-213-0006 x331 [email protected] Media: Justin Jackson 212-213-0006 x327 [email protected]
